September 2007 Volume 3, Issue 9

Volume 3, Issue 9 | September 2007

September 2007

In this Issue

News Briefs

Genomics & Proteomics

Drug Discovery News Placeholder Image

A startup with a pedigree: Alnylam, Isis launch Regulus

Cambridge, Mass.-based Alnylam Pharmaceuticals Inc. and Carlsbad, Calif.-based Isis Pharmaceuticals Inc. have launched Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of miRNA therapeutics.
Drug Discovery News Placeholder Image

A double gain: Epidauros acquisition will boost both of Clinical Data’s genomics divisions

Clinical Data Inc. in late August announced that it had acquired privately held Epidauros Biotechnologie AG of Bernried, Germany, in a cash transaction valued at 8.75 million Euros—or approximately $11.84 million.
Drug Discovery News Placeholder Image

FDA looks to India

GVK Biosciences (GVK Bio) and the U.S. Food and Drug Administration (FDA) signed a material transfer agreement in August under which GVK Bio is granting access to its Clinical Biomarker Database to the FDA.
Drug Discovery News Placeholder Image

Operon, DNA2.0 aim for bigger share of synthetic gene market

Under a new partnership, Operon is providing oligonucleotides to DNA2.0 for the synthesis genes to meet the demands of a market the companies say is expected to double annually for the next several years. The co-marketing agreement calls for cross-selling their core products to their respective customer bases.

Global News

Drug Discovery News Placeholder Image

Bend Research, Pfizer seek to improve drug bioavailability

Bend Research and Pfizer have developed a new delivery technology—-spray-dried dispersions (SDDs)—-that Bend recently announced it will make available to other organizations looking to improve the clinical effectiveness of experimental compounds.
Drug Discovery News Placeholder Image

Ophthotech in-licenses pair of aptamers

In a pair of in-licensing deals with Archemix Corp. and OSI Pharmaceuticals, Ophthotech Corp. recently acquired rights to aptamer compounds for the treatment of macular degeneration. Ophthotech is a new company formed by former executive of Eyetech, which OSI Pharmaceuticals acquired in late 2005.

Informatics

Drug Discovery News Placeholder Image

Getting real with trials

INC Research has partnered with TheraSim, to put together a CPM system that will provide an interactive patient simulation environment designed to both assess and improve the skills and behaviors of clinicians.

Research & Development

Drug Discovery News Placeholder Image

SurModics buys Brookwood for $40 million

SurModics Inc. acquired Brookwood Pharmaceuticals Inc. in a move that combines two portfolios of drug delivery technologies rooted in polymers.
Drug Discovery News Placeholder Image

Modeling drug toxicity

Biological simulations specialist Entelos announced it entered into a CRADA with the U.S. Center for Drug Evaluation and Research (CDER) to develop models of drug-induced liver injury.
Drug Discovery News Placeholder Image

Recent recalls push early tox market

In August, Australia’s Therapeutic Goods Administration asked Novartis AG to pull the pain reliever Prexige from store shelves because of a handful of reports about severe liver reactions in patients taking the drug, including two deaths.
Drug Discovery News Placeholder Image

Magellan BioScience, Thrombotargets team up for marine-isolated microorganism screening

Magellan BioScience Group Inc., and Thrombotargets Corp. recently entered into a drug discovery joint venture agreement that unites an unlimited number of Magellan’s compounds and extracts derived from marine microorganisms with Thrombotargets’ technology for high-throughput screening of pathway activity.

Automation & Instrumentation

Drug Discovery News Placeholder Image

Genotyping for the masses: Applied Bio launches genotyping service provider program for core labs

Looking to both increase the sales of products in its SNPlex line, as well as help its core lab cusotomers provider a wider suite of services to customers, Applied Biosystems Inc. rolled out a service provider program via selected core labs to bring genotyping services to researchers that do not have access to capillary electrophoresis (CE) genetic analysis systems.
Drug Discovery News Placeholder Image

Waters boosts position in thermal analysis market with Calorimetry Sciences acquisition

In a bid to capitalize on the relatively small but growing thermal analysis market in life sciences, Waters Corp. recently acquired Linden, Utah-based Calorimetry Sciences Corp. (CSC), a manufacturer of high-performance calorimeters.
Drug Discovery News Placeholder Image

BioServe breaks out: Develops CRC diagnostic with Phenomenome Discoveries, moves into new HQ

BioServe announced it had developed a novel serum-based diagnostic test with Canadian company Phenomenome Discoveries for the identification of colorectal cancer (CRC), and moved its home base into a new 40,000-square-foot home office that includes wet and dry labs, and is also the home of its Global Repository of more than 600,000 DNA, tissue and serum samples of Genomics Collaborative.
Drug Discovery News Placeholder Image

Cisbio, Lumiphore lighten it up

Cisbio, the developer of HTRF (homogeneous time-resolved fluorescence) technology and start-up biotech, lanthanide specialist Lumiphore Inc., announced early this month an agreement whereby Cisbio will incorporate Lumiphore’s Lumi4 complexes in Cisbio assays.
Drug Discovery News Placeholder Image

PerkinElmer launches assay development service

PerkinElmer announced early last month the launch of a comprehensive assay development service for high-performance, highly sensitive assays in advanced cellular science and drug discovery research.
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue